Salarius Pharmaceuticals Files 8-K on Operations and Equity Sales
Ticker: DCOY · Form: 8-K · Filed: Jul 31, 2025 · CIK: 1615219
Sentiment: neutral
Topics: operations, equity-sale
TL;DR
Salarius Pharma dropped an 8-K on July 31st covering financials and stock sales.
AI Summary
On July 31, 2025, Salarius Pharmaceuticals, Inc. filed an 8-K report detailing results of operations and financial condition, as well as unregistered sales of equity securities. The company, formerly known as Flex Pharma, Inc., is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This filing provides crucial updates on Salarius Pharmaceuticals' financial health and recent equity transactions, which could impact investor decisions.
Risk Assessment
Risk Level: medium — The filing mentions unregistered sales of equity securities, which can sometimes indicate financial distress or dilution concerns.
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- Flex Pharma, Inc. (company) — Former company name
- July 31, 2025 (date) — Date of earliest event reported
- 2450 Holcombe Blvd. Suite X Houston, TX 77021 (location) — Principal executive offices address
FAQ
What specific details are provided regarding the unregistered sales of equity securities?
The filing indicates unregistered sales of equity securities occurred, but the specific details such as the amount, price, or parties involved are not elaborated upon in the provided text.
What is the primary business of Salarius Pharmaceuticals, Inc.?
Salarius Pharmaceuticals, Inc. is in the business of Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
When did Salarius Pharmaceuticals, Inc. change its name from Flex Pharma, Inc.?
The date of the name change from Flex Pharma, Inc. to Salarius Pharmaceuticals, Inc. was July 30, 2014.
What is the fiscal year end for Salarius Pharmaceuticals, Inc.?
The fiscal year end for Salarius Pharmaceuticals, Inc. is December 31st.
What are the two main items reported in this 8-K filing?
This 8-K filing reports on 'Results of Operations and Financial Condition' and 'Unregistered Sales of Equity Securities'.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 31, 2025 regarding Salarius Pharmaceuticals, Inc. (DCOY).